2025年4月28日,复宏汉霖(2696.HK)宣布,公司将在近日召开的2025年美国癌症研究协会(AACR)年会上以壁报形式发布3项自主研发的最新临床前研究成果,包括一款抗PD-L1和抗VEGF双靶点的双特异性抗体HLX37、一项潜在成为同类最佳的KAT6A/B抑制剂候选分子,以及一个同类首创具有特异性杀伤作用的ADC连接子-毒素。 本次AACR大会上发布的研究数据详情如下: HLX37(抗PD-L1/VEGF双抗) 摘要标题:一款兼具免疫检查点抑制、抗血管生成及抗肿瘤活性的新型抗PD-L1/VEGF双特异性抗体HLX37 A novel anti-PD-L1/VEGF bispecific antibody (HLX37) with immune checkpoint inhibition, anti-angiogenic, and antineoplastic activities 分会场标题:Overcoming Checkpoint Inhibition and Tumor Suppression 展示形式:摘要及壁报 摘要编号:7303 展示时间:美国中部时间4月30日(周三)9:00 AM-12:00 PM 展示地点:第39区,展板#18 靶向PD-L1与VEGF的双特异性抗体通过结合肿瘤细胞表面的PD-L1,增强抗VEGF药物向肿瘤部位的递送,从而在肿瘤微环境(TME)中实现血管正常化与T细胞激活的协同效应,最终提升抗肿瘤活性。 HLX37是一款经合理设计的PD-L1/VEGF双特异性抗体。体外研究显示,HLX37对PD-L1和VEGF均具有较高的亲和力,在VEGF存在时可显著促进PD-L1内吞和下调,同时阻断PD-1/PD-L1和VEGF/VEGFR2信号通路,从而促进T细胞激活并抑制肿瘤血管新生。体内研究表明,HLX37在MDA-MB-231(三阴乳腺癌)、NCI-H292(肺癌)等肿瘤模型中呈现剂量依赖的抗肿瘤疗效。与抗VEGF单抗和抗PD-L1单抗的联合用药组相比,HLX37显示出更高的肿瘤富集效应,该效应可能由PD-L1和VEGF共同介导。在食蟹猴毒性实验中,HLX37在100 mg/kg的给药剂量,单周静脉输注3次的频率下表现出良好的耐受性。鉴于HLX37具有优异的临床前抗肿瘤活性且安全性可控,且能增强肿瘤富集效应,其在多类肿瘤中具有广泛的应用潜力。 HLX97(KAT6A/B抑制剂) 摘要标题:一款具有显著抗肿瘤活性及低血液毒性的新型KAT6A/B抑制剂的发现 Identification of novel KAT6A/B inhibitors with enhanced antitumor activity and reduced hematologic toxicity 分会场标题:Lead Identification and Optimization 展示形式:摘要及壁报 摘要编号:6976 展示时间:美国中部时间4月30日(周三)9:00 AM-12:00 PM 展示地点:第25区,展板#5 HLX97是潜在的同类最佳的KAT6A/B抑制剂。KAT6A/B是乳腺癌治疗中极具潜力的靶点。一项针对KAT6A/B抑制剂PF-07248144的I期临床研究显示出积极的疗效,但其靶点相关的血液学毒性(尤其是中性粒细胞减少症)可能限制药物剂量的递增。复宏汉霖致力于开发一款具有“快速起效/快速清除”药代动力学特性的高选择性KAT6A/B抑制剂,旨在最大化药物抗肿瘤活性的同时减轻产品的血液毒性。 与参比化合物PF-07248144相比,HLX97展现出更强的KAT6A/B抑制活性和对KAT5/7/8更高的选择性,并在ZR-75-1细胞模型中产生更强的细胞毒效应。同时,HLX97显示出良好的ADME特性,包括高口服生物利用度和优异的药代动力学特征。在ZR-75-1异种移植模型中,经过五周治疗,HLX97显示出剂量依赖的体内抗肿瘤疗效,且动物体重下降极小。我们认为,HLX97更强的KAT6A/B抑制能力和"相对更快的"体内清除速率可能共同促成了其更宽的治疗窗口。在大鼠单次给药急性毒性试验中,HLX97在100 mg/kg剂量下耐受良好。基于HLX97优异的疗效和安全性特征,复宏汉霖计划于2025年底递交该产品的新药临床试验(IND)申请。 新型ADC连接子-荷载毒素 摘要标题:一款通过持续激活未折叠蛋白反应(UPR)实现独特杀伤机制的新型抗体偶联药物(ADC)连接子-载荷组合的发现 Discovery of a novel antibody-drug conjugate linker-payload with a distinct killing mechanism via prolonged unfolded protein response activation 分会场标题:Drug Design, Synthesis, and Disposition 展示形式:摘要及壁报 摘要编号:5730 展示时间:美国中部时间4月29日(周二)2:00 PM-5:00 PM 展示地点:第25区,展板#1 一类具有3-(4-羟苯基吲哚啉-2骨架结构的化合物,通过持续激活未折叠蛋白反应(UPR),对高表达TRPM4或雌激素受体阳性的癌细胞展现出强效抗肿瘤活性,该杀伤机制与现有毒素不同。此类化合物对多数健康组织毒性较低,主要副作用为胃肠道毒性,代表性化合物包括ErSO和泻药醋酸氧苯乙酯。为克服ADC耐药性,或与现有ADC产生协同,复宏汉霖构建了一类全球首创的ADC 连接子-荷载毒素—我们以此类化合物优化后得到的HLX91-048作为毒素载荷,通过可裂解的GGFG连接子与抗HER2抗体偶联,形成药物抗体比(DAR)为4或8的偶联物。 研究表明,与ErSO相比,HLX91-048的细胞毒性提升了10倍以上,在多类肿瘤细胞中显示出亚纳摩尔至纳摩尔级别的IC50值。相较于DS-8201类似物,基于HLX91-048的抗体药物偶联物(ADC)在多种细胞系中表现出更强的细胞毒性、更显著的旁观者杀伤效应,并且在人及猴血浆中稳定性更高。研究证实,基于HLX91-048的ADC可显著激活未折叠蛋白反应(UPR),与预期一致。基于HLX91-048的DAR4(药物抗体比4)的HER2 ADC在BT474和NCI-N87模型中均显示出剂量依赖性的抗肿瘤效果,在较高剂量(10-12 mg/kg)下实现显著的肿瘤消退。值得注意的是,基于HLX91-048的ADC在部分对DS-8201类似物无应答的耐药患者来源的类器官(PDO)模型中仍保持敏感性。在大鼠临床前毒理学评估中,DS-8201类似物和基于HLX91-048的ADC在60 mg/kg剂量下(每周一次,持续三周)均表现出良好的耐受性。基于HLX91-048的连接子-载荷组合具有高度差异化的作用机制,并在临床前评估中展现出卓越的疗效与安全性。其针对非人灵长类动物的初步毒理学研究已纳入开发计划。 内容来源:AACR官网 关于复宏汉霖 Preclinical Results of Henlius’ Multiple Innovative Candidates Debut at AACR 2025 Shanghai, China, April 28, 2025 – Shanghai Henlius Biotech, Inc. (2696. HK) announced that three latest preclinical research results from its pipeline programs will be published in poster presentations at the American Association for Cancer Research 2025 Annual Meeting (AACR 2025), covering a novel anti-PD-L1/VEGF bispecific antibody HLX37, a novel KAT6A/B inhibitor with best-in-class potential, and a first-in-class ADC linker-payload featuring a highly differentiated killing mechanism. The detailed data of the studies released at AACR 2025 are as follows: HLX37 (anti-PD-L1/VEGF BsAb) Title: A novel anti-PD-L1/VEGF bispecific antibody (HLX37) with immune checkpoint inhibition, anti-angiogenic, and antineoplastic activities Session Title: Overcoming Checkpoint Inhibition and Tumor Suppression Form: Abstract and poster Abstract Number: 7303 Date and Time: April 30, 2025, 9:00 AM-12:00 PM CST Location: Poster Section 39, Board #18 The bispecific antibody targeting PD-L1 and VEGF enhances anti-VEGF delivery to the tumor site by binding to tumor PD-L1, promoting synergistic effects of blood vessel normalization and T cell activation within the tumor microenvironment, thus improving anti-tumor activity. HLX37 is a rationally designed PD-L1/VEGF bispecific antibody. In vitro assays demonstrated that HLX37 exhibits high binding affinity for both PD-L1 and VEGF. In the presence of VEGF, HLX37 dramatically promoted cell surface PD-L1 binding and internalization, showing dual blockade activity against PD-1/PD-L1 and VEGF/VEGFR2, thereby reversing T cell exhaustion and inhibiting tumor angiogenesis. It conferred robust tumor inhibition activity and dose-dependent tumor suppression in the MDA-MB231 and NCI-H292 models. Compared to the combination group of anti-PD-1 monoclonal antibody and anti-VEGF monoclonal antibody, the anti-PD-L1/VEGF bispecific antibody showed enhanced tumor enrichment. The distribution of anti-PD-L1/VEGF is mediated by both PD-L1 and VEGF, HLX37 was well tolerated in cynomolgus monkeys after three weekly intravenous doses of 100 mg/kg. These data suggested that HLX37 has strong preclinical efficacy and favorable safety profile, with enhanced tumor enrichment. HLX37 holds promising potential for further application in various types of cancer. HLX97 (KAT6A/B inhibitor) Title: Identification of novel KAT6A/B inhibitors with enhanced antitumor activity and reduced hematologic toxicity Session Title: Lead Identification and Optimization Form: Abstract and poster Abstract Number: 6976 Date and Time: April 30, 2025, 9:00 AM-12:00 PM CST Location: Poster Section 25, Board #5 HLX97 is a novel KAT6A/B inhibitor with best-in-class potential. KAT6A/B are promising targets for breast cancer therapy. A phase 1 study of the KAT6A/B inhibitor PF-07248144 showed encouraging clinical results; however, target-associated hematologic toxicity, particularly neutropenia, may hinder dose escalation. Henlius aims to identify potent and highly selective KAT6A/B inhibitors with "fast-on, fast-off" pharmacokinetic profiles in vivo, enabling sustained antitumor efficacy while minimizing hematologic toxicity. HLX97 exhibited superior enzymatic inhibition and enhanced selectivity against KAT5/7/8, along with more potent cytotoxic effects in ZR-75-1 cells, in head-to-head comparisons with PF-07248144. Meanwhile, HLX97 displayed favorable ADME characteristics, such as high oral bioavailability and excellent pharmacokinetics. In a ZR-75-1 xenograft model, HLX97 demonstrated dose-dependent antitumor efficacy with minimal weight loss over a five-week treatment period. We propose that the more robust KAT6A/B inhibition and “relatively faster” clearance of HLX97 may contribute to its broader therapeutic window. The compounds were well tolerated at 100 mg/kg in a single-dose acute toxicity study in rats. HLX97 represents a best-in-class KAT6A/B inhibitor with optimized efficacy and safety profiles. An Investigational New Drug (IND) application is anticipated to be submitted by the end of 2025. Novel ADC Linker-payload Title: Discovery of a novel antibody-drug conjugate linker-payload with a distinct killing mechanism via prolonged unfolded protein response activation Session Title: Drug Design, Synthesis, and Disposition Form: Abstract and poster Abstract Number: 5730 Date and Time: April 29, 2025, 2:00 PM-5:00 PM CST Location: Poster Section 25, Board #1 A specific class of compounds featuring a 3-(4-hydroxyphenyl) indoline-2 scaffold demonstrated potent antitumor activity against cancer cells with elevated TRPM4 expression or estrogen receptor positivity through the sustained activation of unfolded protein response. This mechanism is distinct from existing toxins. Generally, these compounds exhibit low toxicity to most healthy tissues, with gastrointestinal toxicity being the primary adverse effect. Notable examples of this class include ErSO and laxative oxyphenisatin acetate. To overcome ADC resistance or synergize with existing ADCs, Henlius dedicated to develop a first-in-class ADC payload—HLX91-048. To create the HER2-targeting ADC, HLX91-048 was linked to a HER2 antibody via a cleavable GGFG linker, resulting in drug-to-antibody ratio (DAR) of 4 or 8 as needed. HLX91-048 demonstrates >10-fold increase in cytotoxicity compared to ErSO, exhibiting sub-nanomolar to nanomolar IC50 values across various tumor cell types. When compared to DS-8201 analog the HLX91-048-based ADC showed enhanced cytotoxicity in multiple cell lines, stronger bystander killing, and greater stability in human and monkey plasma. As expected, the HLX91-048-based ADC significantly activates the unfolded protein response (UPR). The DAR4 HER2 ADC derived from HLX91-048 exhibited dose-dependent antitumor efficacy in both BT474 and NCI-N87 models, leading to substantial tumor regression at higher doses (10-12 mpk). Notably, 5 out of 8 PDOs from patients resistant to various standard treatments remained sensitive to the HLX91-048-based ADC, while showing reduced sensitivity to DS-8201. Lastly, in a pre-toxicology evaluation in rats, both the DS-8201 analog and the HLX91-048-based ADC were well-tolerated at a dose of 60 mpk once weekly for three weeks. The HLX91-048 based linker-payload represents a first-in-class ADC platform featuring a highly differentiated killing mechanism that demonstrated exceptional efficacy and safety in preclinical evaluations. Preliminary toxicology studies in non-human primates have been scheduled. About Henlius 联系方式 媒体:PR@Henlius.com 投资者:IR@Henlius.com 喜欢本文内容 点击下方按钮·分享 ·收藏 ·点赞 ·在看






<END>
*版权声明:本网站所转载的文章,均来自互联网,旨在传递更多信息。鉴于互联网的开放性和文章创作的复杂性,我们无法保证所转载的所有文章均已获得原作者的明确授权。如果您是原作者或拥有相关权益,请与我们联系,我们将立即删除未经授权的文章。本网站转载文章仅为方便读者查阅和了解相关信息,并不代表我们认同其观点和内容。读者应自行判断和鉴别转载文章的真实性、合法性和有效性。
相关资讯
- 综合
多特异性T细胞衔接器:癌症药物开发的新前沿
小药说药
2026-06-22
ATG-125, 德琪的B7H3/PDL1双抗ADC, 可以显著活化T细胞
医药速览
2026-06-21
JCI丨房德玉/孙兆林团队揭示SIRT2–USP22–PD-L1轴驱动肿瘤免疫逃逸的分子机制
BioArtMED
2026-06-21
2026 AACR | 首创(FIC)抗体药物偶联物(ADC)IPN60300 临床前数据公布
Foreseen Biotech
2026-06-21
FDA肿瘤卓越中心发布2025年报,新主任继续引领癌症治疗变革
研发客
2026-06-21
同济大学在 NEJM 和柳叶刀发布 2 项新成果
丁香学术
2026-06-20
Mol Ther:一次治疗,持续保护,细菌训练 NK 细胞建立长期抗转移免疫
丁香学术
2026-06-20
欧洲大佬在CIOT 2026提出:双抗,最可能改变肺癌临床实践
IO笔记
2026-06-20
NK细胞抗癌真相|不是消灭癌症,而是守住身体免疫防线
康思葆细胞免疫研究中心
2026-06-19
NewCo!9300万美元A轮融资,开发Tie2/VEGF双抗
Medaverse
2026-06-19
全球药物研发中心
全球研发数据与行业前沿情报
395,503个
全球在研药物数
0个
本月临床试验数
-
2026-10-31
-
2026-10-30
-
2026-10-30
-
摩熵咨询 33 54
-
摩熵咨询 20 3
-
摩熵咨询 20 10
-
颁布机构:国家药品审评中心(CDE) 2026-10-16
-
颁布机构:国家药品监督管理局药品审评中心 2026-09-28
-
颁布机构:国家药品监督管理局 2026-09-10
最新资讯
- 步长制药AGT小核酸BC923及PD-1/TIGIT双抗BC008-1A同日获批临床,剑指高血压与复发性脑胶质瘤
- 摩熵数科荣获2026年成都市企业技术中心认定!数据+AI双引擎赋能生命科学产业升级
- 先声药业合作品种玛氘诺沙韦上市失利,国产流感创新药竞争格局再迎变局
- 恒瑞医药三季报炸场:归母净利暴增88.92%,创新药持续增长,ADC瑞康曲妥珠单抗第5项适应症获受理
- 诺诚健华Q3营收大增150.60%:BD里程碑收入推高业绩,奥布替尼独挑商业化大梁
- 2026年第43周10.19-10.25全球创新药研发概览
- 2026年第43周10.19-10.25国内医药大健康行业政策法规汇总
- 2026年第43周10.19-10.25国内仿制药/生物类似物申报/审批数据分析
VEGF
当前排名
第156名
13.83分
摩熵指数
0个
新获批上市药物
摩熵指数榜单TOP5
靶点
企业
-
CD19100 -
CD391.57 -
KRAS87.52 -
EGFR77.53 -
PSMA76.5
-
江苏恒瑞医药股份有限公司99.5 -
华润医药集团有限公司98.17 -
正大天晴药业集团股份有限公司97.28 -
上海复星医药(集团)股份有限公司96.32 -
石药控股集团有限公司95.68
添加收藏
新建收藏夹
取消
确认
对不起,您今日剩余下载额度不足,请明日再来!
返回
对不起!您还未登录!请登录后查看




收藏
登录后参与评论
暂无评论